44180 Influence of Baseline Disease Severity Defined by Investigator's Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

Authors

Philip J. Mease
Gülen Hatemi
Maria Paris
Sue Cheng
Peter Maes
Wendy Zhang
Rebecca Shi
Andrea Flower

Recommended Citation

Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, Shi R, Flower A. 44180 Influence of Baseline Disease Severity Defined by Investigator's Global Assessment on Abrocitinib Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study. J Am Acad Dermatol 2023; 89(3):AB181.

Document Type

Conference Proceeding

Publication Date

9-19-2023

Publication Title

J Am Acad Dermatol

Abstract

Background: Long-term efficacy with 48 weeks of abrocitinib treatment has been demonstrated to be comparable to efficacy at week 12 in patients with moderate-to-severe atopic dermatitis (AD). Longer- term efficacy data stratified by baseline disease severity are needed. Patients from JADE-MONO-1, JADE- MONO-2, JADE-COMPARE, JADE-TEEN, and JADE-DARE who were randomly assigned to abrocitinib or placebo and subsequently enrolled into phase 3 long-term extension study JADE-EXTEND (NCT03422822) were analyzed. Data cutoff: September 25, 2021. At the relevant qualifying parent study baseline, Investigator’s Global Assessment (IGA) was moderate in 61% (n=574) and severe in 39% (n=367) of patients treated with abrocitinib 200 mg once daily (QD), and moderate in 64% (n=461) and severe in 36% (n=264) of patients treated with abrocitinib 100 mg QD. After 96 weeks of treatment with abrocitinib 200 mg QD, IGA clear/almost clear was achieved by 61% and 46% of patients in the moderate and severe baseline IGA subgroups, Eczema Area and Severity Index 2:75% improvement (EASI-75) by 86% and 84%, and Peak Pruritus Numerical Rating Scale 2:4-point improvement (PP-NRS4) by 66% and 74%, respectively (as observed). After 96 weeks of treatment with abrocitinib 100 mg QD, IGA clear/almost clear was achieved by 51% and 36% of patients in the moderate and severe baseline IGA subgroups, EASI-75 by 77% and 77%, and PP-NRS4 by 61% and 59%, respectively (as observed). Long- term treatment with abrocitinib to week 96 resulted in clinically meaningful improvement in signs and symptoms of AD for patients with moderate or severe disease at baseline.

Volume

89

Issue

3

First Page

AB181